Product logins

Find logins to all Clarivate products below.


Location Location Location: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry

Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often elective. This differentiating factor is one of many contributing drivers to the noticeable changing site of service for some orthopedic procedures; many orthopedic procedures are moving away from the traditional hospital setting and towards ambulatory surgical centers. As a key stakeholder, medical device firms have to come to grips with this changing landscape and demonstrate the strategic willingness to capitalize on this trend. In spite of the presence of many significant obstacles, including but not limited to challenges to reimbursement in the ASC setting, medical device manufacturers looking to benefit from this site of service shift must adapt their existing portfolios, make an effort to understand the reimbursement and demographic landscape relevant to ASCs, and adjust their pricing and marketing strategies to target ASCs. In so doing, as ASCs assume a more pivotal role in orthopedic care over time, orthopedic medical device companies taking these steps can better ready themselves to effectively compete in the increasingly entrenched orthopedic device market.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…